Clinical Trial Update: Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating the combination of selinexor and olaparib in relapsed/refractory extensive-stage small cell lung cancer is ongoing (Phase 1/Phase 2)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Olaparib (Olaparib)
• Selinexor (selinexor)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Extensive-stage Small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN